Literature DB >> 28194886

Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.

Zhihong Hu1, L Jeffrey Medeiros1, Lianghua Fang1,2, Yi Sun1, Zhenya Tang1, Guilin Tang1, Tsieh Sun1, Andres E Quesada1, Shimin Hu1, Sa A Wang1, Lin Pei1, Xinyan Lu1.   

Abstract

T-cell prolymphocytic leukemia (T-PLL) is an aggressive mature T-cell neoplasm. The most common cytogenetic abnormality associated with T-PLL is inv(14)(q11.2q32) involving TCL1, but other abnormalities also have been reported. In this study, we correlated cytogenetic abnormalities with clinical outcome in 97 T-PLL patients, including 66 men and 31 women with a median age of 63 years (range, 34-81). Twenty-seven patients had a normal karyotype (NK), one had two chromosomal aberrations, and 69 had a complex karyotype (CK). Patients with a CK had poorer overall survival (OS) than patients with a NK (P = .0016). In the CK group, the most common aberrations involved 14q (n = 45) and 8q (n = 38). Additional deletions of chromosomes 17p, 11q, 6q, 12p, 13q were observed frequently. No individual cytogenetic abnormality impacted OS. Patients with ≥5 aberrations had an OS of 11 months versus 22 months in patients with <5 aberrations (P = 0.0132). Fluorescence in situ hybridization for TCL1 successfully performed in 27 cases showed rearrangement in 8/10 (80%) NK versus 16/17 (94%) CK cases. OS of patients with TCL1 rearrangement and/or 14q aberrations was not significantly different from patients without TCL1 rearrangement and 14q aberrations (P = .3467). Patients with refractory disease showed worse OS in both the NK and CK groups (P = .0014 and P < .0001, respectively), compared with patients who achieved remission but then relapsed. Stem cell transplantation did not appear to improve OS regardless of karyotype complexity. In conclusion, patients with T-PLL often have a CK which is a poor prognostic factor, particularly in patients with ≥5 cytogenetic aberrations.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28194886     DOI: 10.1002/ajh.24679

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

2.  Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Authors:  A Schrader; G Crispatzu; S Oberbeck; P Mayer; S Pützer; J von Jan; E Vasyutina; K Warner; N Weit; N Pflug; T Braun; E I Andersson; B Yadav; A Riabinska; B Maurer; M S Ventura Ferreira; F Beier; J Altmüller; M Lanasa; C D Herling; T Haferlach; S Stilgenbauer; G Hopfinger; M Peifer; T H Brümmendorf; P Nürnberg; K S J Elenitoba-Johnson; S Zha; M Hallek; R Moriggl; H C Reinhardt; M-H Stern; S Mustjoki; S Newrzela; P Frommolt; M Herling
Journal:  Nat Commun       Date:  2018-02-15       Impact factor: 14.919

Review 3.  Mature T-Cell leukemias: Challenges in Diagnosis.

Authors:  Dima El-Sharkawi; Ayoma Attygalle; Claire Dearden
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

4.  Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.

Authors:  Nathan Mikhaylenko; Linus Wahnschaffe; Marco Herling; Ingo Roeder; Michael Seifert
Journal:  PLoS One       Date:  2022-09-21       Impact factor: 3.752

Review 5.  Genetic Landscape of Peripheral T-Cell Lymphoma.

Authors:  Vivian Hathuc; Friederike Kreisel
Journal:  Life (Basel)       Date:  2022-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.